336 related articles for article (PubMed ID: 20473859)
1. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers.
Yoshimatsu M; Toyokawa G; Hayami S; Unoki M; Tsunoda T; Field HI; Kelly JD; Neal DE; Maehara Y; Ponder BA; Nakamura Y; Hamamoto R
Int J Cancer; 2011 Feb; 128(3):562-73. PubMed ID: 20473859
[TBL] [Abstract][Full Text] [Related]
2. PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer.
Avasarala S; Van Scoyk M; Karuppusamy Rathinam MK; Zerayesus S; Zhao X; Zhang W; Pergande MR; Borgia JA; DeGregori J; Port JD; Winn RA; Bikkavilli RK
J Biol Chem; 2015 May; 290(21):13479-89. PubMed ID: 25847239
[TBL] [Abstract][Full Text] [Related]
3. CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features.
Elakoum R; Gauchotte G; Oussalah A; Wissler MP; Clément-Duchêne C; Vignaud JM; Guéant JL; Namour F
Biochimie; 2014 Feb; 97():210-8. PubMed ID: 24211191
[TBL] [Abstract][Full Text] [Related]
4. Mouse Models of Overexpression Reveal Distinct Oncogenic Roles for Different Type I Protein Arginine Methyltransferases.
Bao J; Di Lorenzo A; Lin K; Lu Y; Zhong Y; Sebastian MM; Muller WJ; Yang Y; Bedford MT
Cancer Res; 2019 Jan; 79(1):21-32. PubMed ID: 30352814
[TBL] [Abstract][Full Text] [Related]
5. Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway.
Toyokawa G; Cho HS; Masuda K; Yamane Y; Yoshimatsu M; Hayami S; Takawa M; Iwai Y; Daigo Y; Tsuchiya E; Tsunoda T; Field HI; Kelly JD; Neal DE; Maehara Y; Ponder BA; Nakamura Y; Hamamoto R
Neoplasia; 2011 Oct; 13(10):887-98. PubMed ID: 22028615
[TBL] [Abstract][Full Text] [Related]
6. Deep Protein Methylation Profiling by Combined Chemical and Immunoaffinity Approaches Reveals Novel PRMT1 Targets.
Hartel NG; Chew B; Qin J; Xu J; Graham NA
Mol Cell Proteomics; 2019 Nov; 18(11):2149-2164. PubMed ID: 31451547
[TBL] [Abstract][Full Text] [Related]
7. PRMT1 expression is elevated in head and neck cancer and inhibition of protein arginine methylation by adenosine dialdehyde or PRMT1 knockdown downregulates proliferation and migration of oral cancer cells.
Chuang CY; Chang CP; Lee YJ; Lin WL; Chang WW; Wu JS; Cheng YW; Lee H; Li C
Oncol Rep; 2017 Aug; 38(2):1115-1123. PubMed ID: 28656289
[TBL] [Abstract][Full Text] [Related]
8. PRMT6 serves an oncogenic role in lung adenocarcinoma via regulating p18.
Tang J; Meng Q; Shi R; Xu Y
Mol Med Rep; 2020 Oct; 22(4):3161-3172. PubMed ID: 32945431
[TBL] [Abstract][Full Text] [Related]
9. Skeletal muscle-specific Prmt1 deletion causes muscle atrophy via deregulation of the PRMT6-FOXO3 axis.
Choi S; Jeong HJ; Kim H; Choi D; Cho SC; Seong JK; Koo SH; Kang JS
Autophagy; 2019 Jun; 15(6):1069-1081. PubMed ID: 30653406
[TBL] [Abstract][Full Text] [Related]
10. Protein arginine methyltransferase 6 is a novel substrate of protein arginine methyltransferase 1.
Cao MT; Feng Y; Zheng YG
World J Biol Chem; 2023 Oct; 14(5):84-98. PubMed ID: 37901302
[TBL] [Abstract][Full Text] [Related]
11. Loss of the major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other PRMTs.
Dhar S; Vemulapalli V; Patananan AN; Huang GL; Di Lorenzo A; Richard S; Comb MJ; Guo A; Clarke SG; Bedford MT
Sci Rep; 2013; 3():1311. PubMed ID: 23419748
[TBL] [Abstract][Full Text] [Related]
12. Nη-substituted arginyl peptide inhibitors of protein arginine N-methyltransferases.
Lakowski TM; 't Hart P; Ahern CA; Martin NI; Frankel A
ACS Chem Biol; 2010 Nov; 5(11):1053-63. PubMed ID: 20701328
[TBL] [Abstract][Full Text] [Related]
13. PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer.
Yin XK; Wang YL; Wang F; Feng WX; Bai SM; Zhao WW; Feng LL; Wei MB; Qin CL; Wang F; Chen ZL; Yi HJ; Huang Y; Xie PY; Kim T; Wang YN; Hou JW; Li CW; Liu Q; Fan XJ; Hung MC; Wan XB
Oncogene; 2021 Feb; 40(7):1375-1389. PubMed ID: 33420374
[TBL] [Abstract][Full Text] [Related]
14. Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes.
Dowhan DH; Harrison MJ; Eriksson NA; Bailey P; Pearen MA; Fuller PJ; Funder JW; Simpson ER; Leedman PJ; Tilley WD; Brown MA; Clarke CL; Muscat GE
Endocr Relat Cancer; 2012 Aug; 19(4):509-26. PubMed ID: 22673335
[TBL] [Abstract][Full Text] [Related]
15. Understanding protein arginine methyltransferase 1 (PRMT1) product specificity from molecular dynamics.
Gathiaka S; Boykin B; Cáceres T; Hevel JM; Acevedo O
Bioorg Med Chem; 2016 Oct; 24(20):4949-4960. PubMed ID: 27545444
[TBL] [Abstract][Full Text] [Related]
16. Proteome-wide Profiling of Asymmetric Dimethylated Arginine in Human Breast Tumors.
Ma M; Liu F; Miles HN; Kim EJ; Fields L; Xu W; Li L
J Am Soc Mass Spectrom; 2023 Aug; 34(8):1692-1700. PubMed ID: 37463068
[TBL] [Abstract][Full Text] [Related]
17. Methylation of C/EBPα by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer.
Liu LM; Sun WZ; Fan XZ; Xu YL; Cheng MB; Zhang Y
Cancer Res; 2019 Jun; 79(11):2865-2877. PubMed ID: 31015230
[TBL] [Abstract][Full Text] [Related]
18. A novel splicing isoform of protein arginine methyltransferase 1 (PRMT1) that lacks the dimerization arm and correlates with cellular malignancy.
Patounas O; Papacharalampous I; Eckerich C; Markopoulos GS; Kolettas E; Fackelmayer FO
J Cell Biochem; 2018 Feb; 119(2):2110-2123. PubMed ID: 28857308
[TBL] [Abstract][Full Text] [Related]
19. The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis.
Kang D; Cho HS; Toyokawa G; Kogure M; Yamane Y; Iwai Y; Hayami S; Tsunoda T; Field HI; Matsuda K; Neal DE; Ponder BA; Maehara Y; Nakamura Y; Hamamoto R
Genes Chromosomes Cancer; 2013 Feb; 52(2):126-39. PubMed ID: 23011637
[TBL] [Abstract][Full Text] [Related]
20. A remodeled protein arginine methyltransferase 1 (PRMT1) generates symmetric dimethylarginine.
Gui S; Gathiaka S; Li J; Qu J; Acevedo O; Hevel JM
J Biol Chem; 2014 Mar; 289(13):9320-7. PubMed ID: 24478314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
